Video

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

Author(s):

Charu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Related Videos
4 experts are featured in this series.
Related Content
ES-SCLC | catalin – stock.adobe.com
January 6th 2025

Tarlatamab Earns UK Approval for Previously Treated ES-SCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 3rd 2025

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Savolitinib Plus Osimertinib for Pretreated EGFR+ NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 2nd 2025

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification

Lung Cancer | Image Credit: © catalina – stock.adobe.com
January 2nd 2025

European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC